![]() Lung Therapeutics Lung Therapeutics is a biopharmaceutical company developing medicines for unmet medical needs in fibrosis and lung disease. | Vast Therapeutics Vast Therapeutics (formerly Novoclem Therapeutics) is a preclinical-stage pharmaceutical company developing a nitric oxide-based therapy to treat respiratory diseases. | Avanti Biosciences Avanti Biosciences is a biotechnology company that provides therapies for patients with debilitating diseases. | Temisis Therapeutics Temisis Therapeutics is a therapeutic company focusing on the development of small-molecule assets for the treatment of unmet needs in pathologies possessing an inflammatory component. | ||
Founding Date | Founding Date 2011 | Founding Date 2013 | Founding Date 2017 | Founding Date 2009 | Founding Date N/A |
Type | Type Private | Type Private | Type Subsidiary | Type Private | Type Private |
Tags | |||||
Locations | Locations Stevenage, GB HQ Durham, US | Locations Austin, US HQ | Locations Durham, US HQ | Locations San Diego, US HQ | Locations Vandœuvre-lès-Nancy, FR HQ |
Employees | Employees 5 | Employees 10 | Employees 12 | Employees 1 | Employees 2 |
Funding | |||||
Latest funding round | Latest funding round $ 44m (over 5 years ago) | Latest funding round $ 36m (about 7 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A |
Total funding raised | Total funding raised $ 121m | Total funding raised $ 53.9m | Total funding raised $ 15m | Total funding raised N/A | Total funding raised N/A |

Lung Therapeutics is a biopharmaceutical company developing medicines for unmet medical needs in fibrosis and lung disease.
View companyVast Therapeutics (formerly Novoclem Therapeutics) is a preclinical-stage pharmaceutical company developing a nitric oxide-based therapy to treat respiratory diseases.
View companyAvanti Biosciences is a biotechnology company that provides therapies for patients with debilitating diseases.
View companyTemisis Therapeutics is a therapeutic company focusing on the development of small-molecule assets for the treatment of unmet needs in pathologies possessing an inflammatory component.
View company